On November 9, 2020 OncoNano Medicine, Inc. reported positive results from its preclinical study of ONM-400, a novel interleukin-2 (IL-2) encapsulating pH-activated nanoparticle that targets metabolic acidosis of cancer (Press release, OncoNano Medicine, NOV 9, 2020, View Source [SID1234570527]). ONM-400 employs OncoNano’s ON-BOARDTM platform designed to provide tumor specific delivery of a variety of cancer therapeutics. The data, presented today at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 35th Anniversary Annual Meeting, demonstrate successful tumor acidosis-driven accumulation that provides a high local concentration of IL-2 within tumors potentially resulting in an improved therapeutic index for this cancer therapeutic.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"While IL-2 is established as a highly effective solid tumor therapy for treatment of metastatic melanoma and renal cell cancers, the clinical application is greatly hindered by healthy tissue toxicity," said Ravi Srinivasan, Ph.D., President of OncoNano Medicine. "Exploiting low pH relative to normal tissues as a common trait of all solid tumors, ONM-400 has the potential to deliver IL‑2 directly to the tumor microenvironment. We are highly encouraged by these findings and look forward to evaluating ONM-400 in patients."
Presentation Overview
TITLE: ONM-400, a Novel Approach for Interleukin-2 Therapy Using a pH-Activated Nanoparticle Targeting Metabolic Acidosis in Solid Cancers
ABSTRACT ID: 385
LOCATION AND TIME: Virtual Poster Hall, 11/11/2020 – 11/14/2020, 9:00 am – 5:00 pm
PRESENTER: Qingtai Su, Ph.D.
The results announced today are based on in vitro characterization and in vivo demonstration in multiple mice models. Tumor accumulation and biodistribution following intravenous injection (I.V.) of ONM-400 were evaluated in mice bearing head and neck tumors and antitumor efficacy of ONM-400 after I.V. injection was studied in MC38 colon cancer-bearing mice and compared with unencapsulated IL-2 at the same dose. The findings indicate that ONM-400:
Showed high encapsulation efficiency and drug loading density of IL-2
Enabled pH-dependent IL-2 release and bioactivity
Demonstrated successful tumor acidosis-driven release and minimum normal tissue exposure
Allowed for a significantly higher tumor accumulation and lower renal elimination of IL-2 when compared to free IL-2 control
Induced strong antitumor efficacy with complete tumor regression as a monotherapy and a durable antitumor memory effect
About ONM-400
ONM-400 is a next-generation interleukin-2 (IL-2) program that has demonstrated a highly differentiated mechanism of action in preclinical studies. ONM-400 utilizes a proprietary pH-sensitive micelle platform to encapsulate IL-2 and exploit a universal biomarker of all solid cancers – the low pH tumor microenvironment that is acidic relative to normal tissues – to deliver IL-2 directly to the tumor. ONM-400 micelles remain inactive at normal physiological pH until exposure to the acidic tumor microenvironment triggers micelle dissociation and IL-2 release. This has the potential to increase IL-2 accumulation within the tumor while avoiding healthy tissue toxicity, a common challenge of IL-2 therapy.